Flagship Harbor Advisors LLC Purchases 13,725 Shares of COMPASS Pathways PLC Sponsored ADR $CMPS

Flagship Harbor Advisors LLC boosted its position in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 95.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 28,171 shares of the company’s stock after acquiring an additional 13,725 shares during the period. Flagship Harbor Advisors LLC’s holdings in COMPASS Pathways were worth $79,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Woodline Partners LP raised its stake in COMPASS Pathways by 279.9% in the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock valued at $5,019,000 after acquiring an additional 1,292,927 shares during the period. Polar Asset Management Partners Inc. bought a new stake in COMPASS Pathways in the 1st quarter valued at about $657,000. GAMMA Investing LLC raised its stake in COMPASS Pathways by 93.6% in the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock valued at $30,000 after acquiring an additional 5,003 shares during the period. 22NW LP bought a new stake in COMPASS Pathways in the 1st quarter valued at about $1,849,000. Finally, ARK Investment Management LLC increased its position in shares of COMPASS Pathways by 4.0% during the first quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company’s stock valued at $5,162,000 after buying an additional 68,601 shares during the period. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Stock Up 0.3%

CMPS stock opened at $6.32 on Monday. The company has a current ratio of 8.82, a quick ratio of 8.82 and a debt-to-equity ratio of 0.16. The company’s 50 day moving average is $5.68 and its 200 day moving average is $4.60. The stock has a market cap of $606.34 million, a price-to-earnings ratio of -3.43 and a beta of 2.22. COMPASS Pathways PLC Sponsored ADR has a 1-year low of $2.25 and a 1-year high of $7.09.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). Sell-side analysts predict that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on CMPS shares. Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. HC Wainwright reduced their price objective on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, August 4th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 price objective on shares of COMPASS Pathways in a research note on Friday, August 1st. Finally, BTIG Research boosted their price objective on shares of COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.